News & Events about Atea Pharmaceuticals Inc.
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept Results for AT-752 for Dengue Expected 1Q23 Enrollment Expected to Initiate 2Q23 for Phase 2 Combination ...
Atea Pharmaceuticals (NASDAQ:AVIR Get Rating) had its price objective lowered by JPMorgan Chase & Co. from $10.00 to $8.00 in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the stock. A number of other research analysts have also ...
Fool.com Headlines
11 months ago
The stock market was mixed on Monday as investors tried to reconcile everything happening around the world.February came to a close on a mixed note for Wall Street, with investors struggling to deal with all the uncertainty present in the stock market right now. The Dow Jones Industrial Average (...
Companies Reporting Before The Bell
Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
read more...